Detalles de la búsqueda
1.
Empagliflozin in Heart Failure With Predicted Preserved Versus Reduced Ejection Fraction: Data From the EMPA-REG OUTCOME Trial.
J Card Fail
; 27(8): 888-895, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34364665
2.
Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA-REG OUTCOME trial.
Diabetes Obes Metab
; 23(12): 2775-2784, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34463409
3.
Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME® trial.
Eur Heart J
; 41(2): 209-217, 2020 01 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31504427
4.
Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial.
Circulation
; 139(11): 1384-1395, 2019 03 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30586757
5.
Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial.
Circulation
; 140(21): 1693-1702, 2019 11 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-31434508
6.
Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trial.
Cardiovasc Diabetol
; 19(1): 200, 2020 11 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-33243221
7.
Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose-lowering therapy?
Diabetes Obes Metab
; 22(4): 631-639, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31789445
8.
Can the cardiovascular risk reductions observed with empagliflozin in the EMPA-REG OUTCOME trial be explained by concomitant changes seen in conventional cardiovascular risk factor levels?
Diabetes Obes Metab
; 22(7): 1151-1156, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32115840
9.
Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA-REG OUTCOME trial.
Diabetes Obes Metab
; 22(7): 1141-1150, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32227432
10.
Association between uric acid levels and cardio-renal outcomes and death in patients with type 2 diabetes: A subanalysis of EMPA-REG OUTCOME.
Diabetes Obes Metab
; 22(7): 1207-1214, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32030863
11.
Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
Circulation
; 137(2): 119-129, 2018 01 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-28904068
12.
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
N Engl J Med
; 375(4): 323-34, 2016 Jul 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-27299675
13.
A safety update on sodium glucose co-transporter 2 inhibitors.
Diabetes Obes Metab
; 21 Suppl 2: 34-42, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31081590
14.
Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME® trial.
Age Ageing
; 48(6): 859-866, 2019 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31579904
15.
Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial.
Eur Heart J
; 39(5): 363-370, 2018 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29020355
16.
Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial.
Diabetologia
; 61(10): 2155-2163, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-30066148
17.
Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial.
Diabetologia
; 61(8): 1712-1723, 2018 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-29777264
18.
Empagliflozin in women with type 2 diabetes and cardiovascular disease - an analysis of EMPA-REG OUTCOME®.
Diabetologia
; 61(7): 1522-1527, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29713728
19.
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
N Engl J Med
; 373(22): 2117-28, 2015 11 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-26378978
20.
Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
Circulation
; 134(10): 752-72, 2016 Sep 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-27470878